Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Solid Tumor × sargramostim × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 4 Lymphoma, Non-Hodgkin 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Lymphoma 2 Waldenstrom Macroglobulinemia 1 Solid Tumor 1 Skin Neoplasms 1 Sezary Syndrome 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Mycosis Fungoides 1 Lymphoproliferative Disorders 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Extranodal NK-T-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Intraocular Lymphoma 1 Immunoblastic Lymphadenopathy 1 Hodgkin Disease 1 Fallopian Tube Neoplasms 1

Interventions

vistusertib 2 toripalimab 1 tanespimycin 1 sargramostim 1 roniciclib 1 abemaciclib 1 Letrozole 1 Ipilimumab 1 Hydroxychloroquine 1 Fulvestrant 1 Anastrozole 1 Albumin-Bound Paclitaxel 1 AMG 337 1 4-toluenesulfonamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05284214 2023-09-15

SALIENT

Partner Therapeutics, Inc.

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡